Rheumatology | Texas

Rheumatology billing where a single infusion error costs more than a month of claims.

In rheumatology the drug is usually worth more than the visit. T Zync protects the infusion suite: authorization before the chair is booked, drug units that match the NDC, and underpayment review against the contracted rate.

A billing team reviewing rheumatology infusion claims and biologic authorizations
Designed for Independent rheumatology practices running in-office infusion services in Texas No PHI through public forms

01 Why rheumatology is different

Buy-and-bill means the practice carries the inventory risk.

A rheumatology practice that purchases biologics and bills them after administration is financing the drug. When an infusion is given against an expired authorization, or billed with units that do not match the NDC, the denial is not a delayed payment. It is a loss equal to the acquisition cost of the drug.

The second exposure is quieter. Biologics are reimbursed against payer-specific contracted rates, and underpayments on high-cost drugs are easy to miss because the claim technically paid. Without line-level rate comparison, the shortfall is absorbed silently, month after month.

T Zync manages both: authorization and reauthorization before the chair is booked, and payment validation against the contracted rate after it is billed.

02 What we handle

The full rheumatology revenue cycle.

01

Infusion authorization

Secure approval before scheduling, with the exact drug, dose and administration codes that will be billed.

02

Reauthorization tracking

Calendar approval expiry and remaining units so no patient is infused on a lapsed approval.

03

Drug and administration coding

Bill the J-code and administration codes together, with units reconciled to the NDC and dose given.

04

Wastage and modifier compliance

Apply discarded-drug and single-dose container modifiers as payers require.

05

Biosimilar handling

Bill the specific biosimilar dispensed, and track payer preference policies that change which product is covered.

06

Joint injection billing

Code aspiration and injection procedures with correct guidance rules and bundling awareness.

07

Underpayment review

Compare biologic payments line by line against contracted rates rather than accepting a paid status.

08

Denial recovery

Work authorization, unit and policy denials against filing deadlines before they become unrecoverable.

03 Codes that carry rheumatology revenue

The code families this work lives in.

Rheumatology billing concentrates in the infusion suite, where code accuracy and drug units carry the most financial weight.

Rheumatology code families and what each covers
Code familyWhat it covers
96365, 96366Intravenous infusion for therapy or diagnosis, initial hour and each additional hour.
96413, 96415Infusion administration for agents payers classify as complex, initial hour and each additional hour.
96372Therapeutic or diagnostic injection, subcutaneous or intramuscular.
J1745 and its biosimilarsInfliximab and the biosimilar products billed under their own HCPCS codes, where the product dispensed must match the code billed.
J0129, J3262, J1602Abatacept, tocilizumab and intravenous golimumab, each with their own unit definitions.
J9312, J0490, J2507Rituximab, belimumab and pegloticase, all high-cost agents where unit errors are expensive.
JW and JZ modifiersDiscarded drug reporting and the attestation that no amount was discarded from a single-dose container.
20600–20611Arthrocentesis, aspiration and injection of small, intermediate and major joints, with and without ultrasound guidance.
77080, 86200, 86431, 86038Bone density study and the serology commonly ordered alongside rheumatology evaluation and monitoring.

Codes listed reflect common documentation scenarios in this specialty and are shown for orientation. Correct code selection always depends on the documentation, the payer's policy and the current code set for the year of service. T Zync verifies current payer policy at the time of billing.

04 How it runs

Protection before the chair is booked.

  1. 01

    Authorize

    Confirm approval, units and expiry against the exact codes to be billed before scheduling.

  2. 02

    Administer and capture

    Record dose, units and wastage at the point of administration, not from memory afterwards.

  3. 03

    Bill accurately

    Submit drug and administration codes together with NDC-matched units and required modifiers.

  4. 04

    Validate payment

    Compare payment against the contracted rate and pursue underpayments as actively as denials.

05 Texas payer landscape

The payers and deadlines that decide a Texas claim.

In rheumatology a missed deadline is not a lost visit fee, it is the acquisition cost of a biologic. These are the rules that decide whether a balance is still recoverable.

Texas payers and the filing rules that apply to each
Payer or ruleWhat it means for your claims
Medicare – Novitas Solutions (Jurisdiction H)The Part B contractor for Texas. Claims carry a twelve-month timely filing limit from the date of service, and a redetermination must be requested within 120 days of the initial determination notice.
Texas Medicaid (TMHP)Fee-for-service claims must be filed within 95 days of the date of service, one of the shortest limits in the country and a frequent cause of unrecoverable Texas denials.
Medicaid managed care (STAR, STAR+PLUS)Each managed care plan applies its own filing, authorization and appeal rules on top of state policy, so payer-specific edits matter more than a single Medicaid workflow.
Texas prompt payState-regulated HMO and PPO plans carry statutory deadlines for paying clean claims, which gives a documented clean submission real leverage in follow-up.
Commercial and Medicare AdvantageFiling limits are contract-specific and commonly range from 90 to 180 days, so the follow-up calendar should be driven by the contract rather than by habit.
Drug claims and appeal windowsHigh-cost drug denials carry the same appeal deadlines as any other claim, but far greater value per claim, which is why infusion denials are worked first rather than by age.

Filing limits and appeal windows are set by payer policy and by contract, and they change. T Zync verifies the applicable deadline per payer at the time of work.

FAQ Rheumatology billing guidance

Rheumatology billing questions, answered clearly.

For guidance specific to your specialty, payer mix and systems, speak with T Zync.

Ask T Zync a question

Why are infusion claims denied even with an approved authorization?

Usually because something on the claim does not match the approval. Common causes are a different administration code than the one approved, drug units that do not reconcile to the NDC and dose, a lapsed approval date, or a biosimilar dispensed under a payer policy that prefers a different product.

What is Texas gold carding, and does it apply to my practice?

Texas law requires state-regulated health plans to exempt a physician from prior authorization for a service when the physician's approval rate for that service is consistently high over the evaluation period. It applies to state-regulated plans, not to self-funded ERISA plans or Traditional Medicare, so exemption status has to be tracked per plan.

When is the JZ modifier required?

When a single-dose container is used and no amount was discarded, payers require the attestation modifier on the claim. Discarded amounts are reported separately. Missing this reporting is a frequent and entirely avoidable denial in infusion practices.

Do you track reauthorization dates for biologic patients?

Yes. Approval expiry and remaining units are calendared per patient, and renewals are started before the current approval lapses, since an infusion given on a lapsed approval is generally unrecoverable.

How do you catch biologic underpayments?

By comparing each drug line against the payer's contracted rate rather than treating a paid claim as a closed claim. On high-cost agents, a small per-unit shortfall becomes a significant annual loss.

Can you handle white-bagging and payer-preferred product policies?

Yes. Payer policies that redirect the drug supply or mandate a specific biosimilar are tracked per plan, since they change both the authorization path and what the practice may bill.

Start with clarity

What did your last denied infusion actually cost the practice?